As COVID-19 seems to be making a comeback in many areas of the world, including Japan, a new study published on the preprint server medRxiv* in October 2020 shows the relevance of microsamples of ...
MeMed Severity™ has received FDA Breakthrough Device Designation as a host-response test designed to predict severe outcomes up to 72 hours and mortality 14 days in advance in patients with acute ...
A new needle-free blood test, TAP, launched by UHMBT NHS Trust, transforms care for patients with learning disabilities or needle phobia ...
In some embodiments, the method comprises providing a first low volume, capillary blood sample (or any low volume blood sample and/or any blood sample not obtained from a vein or by venipuncture) ...
AUSTIN, Texas--(BUSINESS WIRE)--Babson Diagnostics (Babson), a transformative medical technology company, is improving the way the public receives diagnostic blood testing. According to the CDC, 70% ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results